Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galantamine add-on to second-generation antipsychotics for negative symptoms of schizophrenia
IRCT20181117041682N2Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jan 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Galantamine add-on with Placebo add-on (2 arms). Primary endpoint: Negative symptoms of schizophrenia. Started Jan 2019; status: completed.
02
Drugs
galantamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20181117041682N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181117041682N2.